Delal Akdeniz is a cancer researcher at Erasmus MC's Department of General Practice, focusing on contralateral breast cancer risk in BRCA carriers. Her work combines epidemiological methods with clinical oncology to inform prevention strategies. Key studies examine radiation and chemotherapy impacts on secondary cancer development using nationwide cohorts. She contributes to international collaborations like HEBON (Hereditary Breast and Ovarian Cancer Research Netherlands), developing risk prediction models for high-risk populations.
Eric Polley is an Associate Professor in the Department of Public Health Sciences at the University of Chicago, serving as Director of the Biostatistics Laboratory. He leads the Data Science concentration in the Master of Public Health program. Previously, he held roles at the Mayo Clinic and the National Cancer Institute (NCI), where he contributed to the NCI-MATCH clinical trial, earning him the 2015 NCI Director's Award. Education: Bachelor of Arts in Mathematics, Saint John's University (2003) Master of Science in Biostatistics, Columbia University (2005) PhD in Biostatistics, University of California, Berkeley (2010) Fellowship in Computational Biology, National Cancer Institute (2012) Research Interests: Dr. Polley specializes in developing and evaluating prediction models for clinical outcomes, particularly in oncology and precision medicine. His work focuses on diagnostic/prognostic methods, germline variant analysis, and clinical trial design. He has pioneered the Super Learner ensemble prediction methodology and contributed to understanding genetic risk factors in breast and pancreatic cancers. Key Contributions: Leader in integrating machine learning with clinical data (e.g., EHR-based fracture prediction) Expert in analyzing germline variants for cancer risk stratification Co-developed the NCI-MATCH trial framework for precision oncology Grants & Labs: Directs the Biostatistics Laboratory, collaborating on genomic studies and clinical trial design. Active in multi-institutional projects addressing cancer disparities and genetic predisposition.
Constantine A Gatsonis is the Henry Ledyard Goddard University Professor of Statistical Sciences and founding Director of Brown University’s Center for Biostatistics and Health Data Science. Educated at Princeton (BA) and Cornell (MS, PhD), he has been a Brown faculty member since 1995. His roles include: Network Statistician for ACRIN (1999–present) Group Statistician for ECOG-ACRIN Statistical Consultant for the New England Journal of Medicine (since 2016) Founding Editor-in-Chief of Health Services and Outcomes Research Methods Associate Editor for Annals of Applied Statistics and Academic Radiology Education PhD, Cornell University (1981) MS, Cornell University (1978) BA, Princeton University (1976, Phi Beta Kappa) Research Interests Dr. Gatsonis is a world leader in statistical methods for diagnostic test evaluation and comparative effectiveness research. His work focuses on: ROC analysis for detection and prediction Bayesian methods in biomedical research Meta-analysis of diagnostic test accuracy Medical imaging biomarkers and radiomics Health services and outcomes research He leads methodological development for cancer care delivery and cardiovascular disease studies through ACRIN and ECOG-ACRIN networks. Article Trends Dr. Gatsonis’s 250+ publications span Bayesian statistics , ROC methodology , and clinical trial design for imaging biomarkers. Key trends include: Development of statistical frameworks for multi-center trials (e.g., DMIST, NLST, TMIST) Advancements in quantitative imaging biomarkers and radiomics validation Focus on comparative effectiveness in cancer screening (lung, breast, cervical) and cardiovascular imaging Methodological contributions to meta-analysis and health technology assessment Scientific Awards Fellow, American Statistical Association (1998) Long-Term Excellence Award, Health Policy Statistics Section, ASA (2015) Spinoza Visiting Professor, Academic Medical Center, University of Amsterdam (2003) National Research Service Award, NIMH (1986–1988) Fellow, Association for Health Services Research (1997) Leadership & Grants Director, Brown Biostatistics Center of ACRIN (1999–present) Co-PI, ECOG-ACRIN Network Group Statistics and Data Management Center (U10 CA180794, 2014–2019) Subcontract PI, ECOG-ACRIN NCORP Research Base projects (UG1 CA189828, 2014–2025) Co-PI, Tomosynthesis Mammography Imaging Trial (UG1 CA189828, 2016–2025) Labs & Collaborations He directs the Center for Biostatistics and Health Data Science at Brown and collaborates with major networks: ACR Imaging Network (ACRIN, now ECOG-ACRIN) Quantitative Imaging Biomarkers Alliance (QIBA, RSNA) Cochrane Diagnostic and Screening Test Methods Working Group NIH/National Academies committees on forensics, reproducibility, and cancer research
Dr. Koos Boeve is a researcher at the University Medical Center Groningen (UMCG) within the Faculty of Medical Sciences, affiliated with both the Molecular Oncology (MO) and Personalized Cancer Treatment (PCT) research groups. His work significantly contributes to UN Sustainable Development Goals related to health and well-being. His research focuses on oral cancer diagnostics and treatment, with particular expertise in sentinel lymph node biopsy techniques, mouth squamous cell carcinoma, and neck-related oncology. Dr. Boeve's work addresses critical challenges in identifying high-risk patients and optimizing treatment strategies for early-stage oral cancers. Analysis of his recent publications reveals a strong emphasis on risk stratification for non-smoking/non-drinking oral cancer patients, molecular markers for treatment personalization, and comparative effectiveness of different surgical approaches for early-stage oral cancers. His work bridges clinical practice with molecular oncology to improve patient outcomes. Dr. Boeve actively collaborates with researchers across multiple institutions, as evidenced by his co-authorship on studies involving teams from various medical centers. His research output demonstrates consistent contributions to the field of head and neck oncology over the past several years.
Clinical Associate Professor at the University of Copenhagen's Faculty of Health and Medical Sciences, Department of Clinical Medicine (Urology section), affiliated with Rigshospitalet (Region Hovedstaden). Current contact: Phone +4560247951, Email jan.viberg.jepsen@regionh.dk, Address Blegdamsvej 3, 2200 Copenhagen N. Research focuses on advancing surgical techniques through robotic-assisted systems, medical education innovation, and urological/nephrological outcomes. Key areas include: Development of simulation-based surgical training curricula Validation of robotic surgery assessment tools Interprofessional veterinary-human surgical collaboration Postoperative renal function in endocrine surgery Oncological outcomes in minimally invasive urological procedures Recent publications (2017-2024) demonstrate strong emphasis on surgical education methodology and technical validation, particularly in robotic prostatectomy and cross-specialty training frameworks. Research integrates clinical practice with educational theory to improve surgical competency assessment. No scientific awards or formal student advising roles are documented in the source materials. Current work involves collaboration with surgical education experts (e.g., Konge, Bjerrum) and clinical teams across urology/endocrinology disciplines.
Alexander Ploner is a Researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet since 2011. His work focuses on biostatistics, epidemiology, and bioinformatics with applications in medical research. Dr. Ploner received his Doctorate in Technical Sciences from the Technical University of Vienna in 2000 and completed his Diplom-Ingenieur (B.S. and M.S.) in Mathematics from the same institution in 1995. Ploner's research primarily centers on the analysis of molecular data and its clinical and epidemiological applications. His work involves gene expression microarrays and SELDI-TOF mass spectrometry, particularly in cancer research. He develops statistical methods to address the challenges of high-dimensional data and multiple testing, with a focus on false discovery rate variants. A strong advocate for practical implementation, he maintains several R packages available through the Bioconductor repository, bridging theoretical statistics with real-world applications in medical research. His publication record demonstrates consistent contributions across multiple domains including psychiatric genetics, cancer epidemiology, aging research, and vaccine effectiveness. Recent work shows an increasing focus on interdisciplinary research connecting genetics, epidemiology, and clinical outcomes, with particular attention to mental health disorders, cancer risk factors, and the biological mechanisms of aging. Dr. Ploner has supervised at least one doctoral student, Maria Sandberg (Schelin), whose 2007 thesis focused on "Contralateral Breast Cancer - Risk and Prognosis." His collaborative approach is evident in his extensive co-authorship across numerous high-impact studies, reflecting engagement with multiple research teams and projects at Karolinska Institutet.
Jennifer Hay is an active researcher affiliated with the School of Cancer Sciences at the University of Glasgow. Her work spans two primary research domains: colorectal cancer pathology and traumatic brain injury. She maintains an active research profile with numerous publications in high-impact journals across these fields. Her research interests focus on tumor microenvironment analysis in colorectal cancer, particularly the development and validation of the Glasgow Microenvironment Score as a prognostic tool. She investigates histopathological scoring methods, immune infiltration patterns, and molecular pathways in colorectal cancer. Earlier in her career, she conducted significant research on blood-brain barrier pathology and long-term neurological consequences following traumatic brain injury. Analysis of her recent publications (2023-2025) reveals a strong concentration on colorectal cancer research, with particular emphasis on tumor-stroma interactions, histopathological scoring systems, and the development of prognostic biomarkers. Her work frequently employs advanced techniques including multiplex immunofluorescence, spatial transcriptomics, and computational pathology approaches to characterize tumor microenvironments. Hay collaborates extensively with Professor Joanne Edwards and other researchers at the University of Glasgow, particularly within the cancer research community. Her work contributes significantly to understanding how tumor microenvironment characteristics influence cancer progression, recurrence patterns, and treatment response in colorectal cancer patients.
Hiroo Suami is an Associate Professor in the Department of Health Sciences at Macquarie University, affiliated with the Australian Lymphatic Education, Research and Treatment (ALERT) Centre. He holds a dual MD and PhD, specializing in reconstructive microsurgery and lymphatic system research. His career includes roles at the University of Melbourne (2001–2009) and MD Anderson Cancer Center (2009–2015) before joining Macquarie University in 2015. Education: Trained in Japan as a reconstructive microsurgeon, admitted to the Japan Society of Plastic and Reconstructive Surgery (1999). Developed lymphatic imaging techniques at the University of Melbourne, including radiographic methods for cadaver models and indocyanine green (ICG) lymphography. Research focuses on lymphedema pathophysiology, lymphatic anatomy, and clinical applications of ICG lymphography. Key projects include studies on lymphatic drainage patterns in cancer patients, diagnostic tools for lymphatic disorders, and personalized lymphedema management strategies. Recent articles emphasize lymphatic collateralization after surgery, ICG-guided imaging protocols, and lymphatic pathways in melanoma and breast cancer. Awards include the 2005 Basic Science Award from the Plastic Surgery Education Foundation. Active in global collaborations, Suami has delivered over 60 invited talks on lymphatic anatomy and clinical applications.
Peter Sinnige is a researcher at the University Medical Center Groningen (UMCG), University of Groningen, specializing in neuro-oncology and radiation therapy with focus on low-grade glioma management and advanced imaging applications. His work bridges clinical oncology and neuroscience to optimize therapeutic outcomes. Research expertise includes: Neuro-oncology and brain tumor radiation therapy Advanced neuroimaging (DTI, FLAIR, DWI) for treatment monitoring Radiation dose distribution analysis in cerebral tissue Proton therapy applications in urological cancers Neurocognitive impact of radiotherapy Recent publications demonstrate strong interdisciplinary integration of radiation oncology and neuroscience, emphasizing spatial mapping of radiation effects using MRI biomarkers to personalize therapy while minimizing neurotoxicity. Current work validates imaging models for predicting treatment response in post-surgical glioma patients. Sinnige actively collaborates within UMCG's oncology research teams, contributing to clinical studies that inform radiotherapy protocols for brain and testicular cancers through academic presentations and peer-reviewed publications.
Dinny Graham is a Senior Research Fellow at the Westmead Clinical School , University of Sydney. A distinguished cancer researcher, Graham's work focuses on breast cancer and nuclear receptor signaling , particularly progesterone and mineralocorticoid receptors . Their research integrates molecular biology and computational biology to unravel hormone-driven cancer mechanisms. Research Themes : Cancer, Breast Cancer, Computational Biology Approaches : Cellular/Molecular, Receptor Biology Recent publications analyze cancer subtyping via federated deep learning , the mineralocorticoid receptor's role in oncogenesis, and AI-based pathology scoring for triple-negative breast cancer. Graham's team explores drug delivery systems and metabolic reprogramming in clinical contexts. Honorifics include grants from NSW Health , Cancer Institute NSW , and Tour de Cure Ltd . Current research students— Rafia ALI , Mona MIRZAEIMILANI , and Yiting WANG —investigate biomimetic nanoparticles, EMT-immunotherapy interactions, and drug response modeling.
Daniel Barnes is a Senior Research Associate statistician at the Centre for Cancer Genetic Epidemiology within the Department of Public Health and Primary Care at the University of Cambridge, where he has been working since 2016. He holds Chartered Statistician (CStat) accreditation from the Royal Statistical Society and is actively involved in international research collaborations including CIMBA, BCAC, and OCAC. Current Affiliation: Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge Previous Positions: Statistician at MRC Epidemiology Unit, Research Associate at Cardiovascular Epidemiology Unit Education: BSc and MSc from University of Leicester, PhD from University of Cambridge Dr. Barnes' research focuses on genetic epidemiology, medical statistics, and statistical genetics, with particular emphasis on understanding modifiers of cancer risk for BRCA1 and BRCA2 pathogenic variant carriers. His work primarily investigates breast, ovarian, and prostate cancer risks using genome-wide association studies and polygenic risk score methodologies. His research has significant implications for personalized cancer risk prediction and prevention strategies for individuals with high-risk genetic mutations. Analysis of his recent publications shows a consistent focus on genetic modifiers of cancer risk, with particular attention to how polygenic risk scores can refine risk prediction for BRCA1/BRCA2 mutation carriers. His work spans multiple cancer types and has contributed to large-scale international consortia efforts to identify genetic risk factors. Chartered Statistician (CStat) accreditation from the Royal Statistical Society Multiple high-impact publications in JAMA, Nature Communications, and Journal of the National Cancer Institute Dr. Barnes' research is supported through collaborative international consortia funding, with primary work conducted through the Centre for Cancer Genetic Epidemiology. His methodology-focused approach to analyzing genetic associations with cancer risk has positioned him as a key contributor to large-scale genetic epidemiology studies. The Centre for Cancer Genetic Epidemiology provides a rich interdisciplinary environment for his work, connecting statistical methodology with clinical applications in cancer prevention.
Eva Browne is a Researcher in the Department of Veterinary and Animal Sciences at the University of Massachusetts Amherst . She works in the lab of Dr. Kathleen Arcaro on DNA methylation patterns, cytokine analysis, and biomarker discovery for breast cancer risk. Current Projects : Biomarkers in white blood cell methylation for breast cancer risk. Past Projects : DNA methylation in breast milk, cytokine profiling, BPA exposure studies. Research Interests center on epigenetics , cancer biomarkers , and environmental health through molecular analysis of breast milk and blood samples. Her work bridges biochemistry and public health by exploring methylation patterns and dietary interventions. Publications include studies on DNA methylation in breast milk, cancer-related protein expression , and adhesive cell capture devices . Her articles span 2008–2024 , with recent focus on biomarker discovery and inflammatory factors . Her lab work includes non-clinical microfluidic cell isolation and longitudinal cohort studies like the PLCO Cohort analysis. She also contributes to veterinary sciences via fish health studies (e.g., Chinook salmon exposure biomarkers).
Dr. Hiroyuki Abe is a distinguished Professor of Radiology at the University of Chicago, specializing in breast imaging and advanced MRI techniques. With medical training completed at Tohoku University in Japan (MD 1987, PhD 1996) followed by radiology residencies and a fellowship in Breast Imaging at the University of Chicago (2005), Dr. Abe has established himself as a leading researcher in quantitative breast imaging analysis. His research focuses on several critical areas in breast cancer imaging: Dynamic contrast-enhanced MRI (DCE-MRI) for improved cancer detection Quantitative assessment of background parenchymal enhancement Axillary lymph node evaluation in breast cancer patients Computer-aided diagnosis systems for breast lesions Application of artificial intelligence in breast imaging interpretation Standardization of imaging protocols across institutions Dr. Abe's publication record demonstrates consistent high-impact research, with a particular emphasis on translating quantitative imaging biomarkers into clinical practice. His work spans from fundamental physics of MRI acquisition to clinical implementation in multi-center trials, with significant contributions to understanding how imaging features correlate with cancer biology and treatment response. His numerous awards from the Radiological Society of North America reflect the significance of his contributions to the field, including multiple Certificate of Merit awards, a Research Fellow Award, and a Cum Laude Award. He has also been recognized as a Distinguished Reviewer by the American Journal of Roentgenology. Dr. Abe has been instrumental in major clinical trials including the I-SPY 2 TRIAL, where his expertise in quantitative imaging biomarkers has helped advance personalized treatment approaches for breast cancer patients. His collaborative work extends across multiple institutions, consistently pushing the boundaries of what's possible in breast cancer imaging and diagnosis.
Dr. Maartje Hooning is a Principal Investigator and Research Group Leader at the Department of Medical Oncology, Erasmus University Medical Center (affiliated with Erasmus University Rotterdam). She earned her medical degree from the University of Amsterdam (1990), followed by an MSc in Clinical Epidemiology and a PhD in Cancer Epidemiology from the Netherlands Cancer Institute. Since 2006, she has served as a senior scientist at Erasmus MC, where she leads the research group 'Epidemiology of Hereditary Cancer' in collaboration with Dr. Agnes Jager. Her research integrates genotype, hormonal factors, tumor characteristics, and treatment data to develop risk assessment and prognostic models for hereditary breast and ovarian cancer. This work aims to optimize clinical decision-making for high-risk families. She is an active steering committee member of HEBON (Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer) and represents the Rotterdam Breast Cancer Study in the international Breast Cancer Association Consortium (BCAC). Her publications focus on hereditary cancer risk mitigation, including contralateral breast cancer prevention, effects of risk-reducing surgeries, and radiation-associated risks in BRCA carriers. Methodologies include systematic reviews, prospective cohort studies, and meta-analyses that inform clinical guidelines. Key Grants & Funding: KWF (2017): CHEK2 c.1100delC families' breast cancer risk prediction KWF (2016): Outcomes of risk-reducing salpingo-oophorectomy Pink Ribbon (2016): Impact of bilateral risk-reducing mastectomy Alpe d’HuZes/KWF (2014): Online decision aid for contralateral breast cancer Pink Ribbon (2012/2008): Contralateral breast cancer risk in BRCA carriers NWO (2009): HEBON research infrastructure Research Groups: Breast Cancer Genomics and Proteomics; ACE Academisch Borstkanker Centrum; ACE Gynaecologische tumoren. Supervision: Co-promotor for PhD candidate B.A.M. Heemskerk-Gerritsen (2014).
Nikhil Rammohan is an Assistant Professor of Radiation Oncology at the Washington University School of Medicine , affiliated with the Brain Tumor Center and Siteman Cancer Center. His research focuses on advanced imaging analytics to optimize cancer therapy and assess treatment-related toxicity. BS, MSE: Johns Hopkins University (2008-2009) MD/PhD: Northwestern University Feinberg School of Medicine (2018) Residency: Northwestern University (2023) Research interests span MRI-based radiomics , theranostics , and deep learning applications in treating CNS and head & neck malignancies. Recent work emphasizes MR-Linac technology , adaptive radiotherapy , and structural brain changes post-radiotherapy. Scientific awards include Teacher of the Year (2024-2025) and ARRO Educator of the Year . His publications highlight innovations in molecular MRI , cancer prognosis modeling , and radiation oncology hardware .
